Private Grünenthal Aims For Leadership In Pain
Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.
You may also be interested in...
Germany’s family-owned pain specialty company Grunenthal – already bracing for an expected fall in sales due to the loss of exclusivity on its best-selling product – now finds itself searching for a new CEO as well.
Stada spends $537 million on Grünenthal's branded product portfolio in Central and Eastern Europe and Spirig's generics business in Switzerland.
Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe
German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.